Recent advances in understanding and treating vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
---|---|
Enthalten in: |
F1000Research - 5(2016) vom: 01. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Koster, Matthew J [VerfasserIn] |
---|
Links: |
---|
Themen: |
ANCA-associated vasculitides |
---|
Anmerkungen: |
Date Completed 27.06.2016 Date Revised 13.11.2018 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.12688/f1000research.8403.1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM261791109 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM261791109 | ||
003 | DE-627 | ||
005 | 20231224200325.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.12688/f1000research.8403.1 |2 doi | |
028 | 5 | 2 | |a pubmed24n0872.xml |
035 | |a (DE-627)NLM261791109 | ||
035 | |a (NLM)27347395 | ||
035 | |a (PII)F1000 Faculty Rev-1436 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Koster, Matthew J |e verfasserin |4 aut | |
245 | 1 | 0 | |a Recent advances in understanding and treating vasculitis |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.06.2016 | ||
500 | |a Date Revised 13.11.2018 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a ANCA-associated vasculitides | |
650 | 4 | |a B-cell | |
650 | 4 | |a systemic vasculitides | |
650 | 4 | |a vasculitis | |
700 | 1 | |a Warrington, Kenneth J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t F1000Research |d 2012 |g 5(2016) vom: 01. |w (DE-627)NLM22994549X |x 2046-1402 |7 nnns |
773 | 1 | 8 | |g volume:5 |g year:2016 |g day:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.12688/f1000research.8403.1 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 5 |j 2016 |b 01 |